What is Imbed Biosciences?
Imbed Biosciences is a privately held medical device company dedicated to revolutionizing wound care through its proprietary Synthetic Antimicrobial Matrix (SAM) technology. This advanced platform integrates antimicrobial and bioactive agents to create matrices that not only protect wounds but also actively support the healing process while managing pain. The company's solutions are designed for a broad spectrum of wound types, including chronic, acute, surgical, and burn wounds. Registered with the U.S. FDA and adhering to international quality standards, Imbed Biosciences is positioned to address critical unmet needs in the global wound care market.
How much funding has Imbed Biosciences raised?
Imbed Biosciences has raised a total of $18.5M across 7 funding rounds:
Private Equity
$683K
Grant
$1.5M
Debt
$600K
Private Equity
$1.6M
Series A
$4M
Debt
$150K
Debt
$10M
Private Equity (2014): $683K, investors not publicly disclosed
Grant (2014): $1.5M led by National Institute for Arthritis and Musculoskeletal and Skin Di
Debt (2016): $600K, investors not publicly disclosed
Private Equity (2017): $1.6M, investors not publicly disclosed
Series A (2019): $4M backed by WISC Partners and Formidable Asset Management
Debt (2020): $150K with participation from PPP
Debt (2024): $10M led by Niterra and Pegasus Tech Ventures
Key Investors in Imbed Biosciences
WISC Partners
WISC Partners is an investment firm focused on providing strategic operating capital to entrepreneurs capable of addressing significant challenges. They offer expansion and acceleration capital, emphasizing a high level of post-investment engagement to support their portfolio companies. Their unique partnership with the UW-Madison College of Engineering enhances their ability to connect public research with private enterprise.
Niterra
Niterra Ventures is an open innovation lab that transforms entrepreneurial ideas into reality by combining expert knowledge and technology. The company focuses on investments in various sectors, including mobility, energy, sustainability, medical, and communications, aiming to drive long-term value and societal impact. They collaborate with leading innovators and businesses globally to redefine industries and tackle new challenges.
National Institute for Arthritis and Musculoskeletal and Skin Di
The National Institutes of Health (NIH), founded in 1887 and based in Bethesda, Maryland, is an agency of the United States Department of Health and Human Services and is the primary agency of the United States government responsible for biomedical and health-related research.
What's next for Imbed Biosciences?
With its recent major enterprise-level funding, Imbed Biosciences is poised for a significant growth phase. The capital infusion is anticipated to accelerate the commercialization of its SAM technology, potentially expanding its product pipeline and market reach. Strategic investments in research and development, coupled with enhanced sales and marketing efforts, will likely be key priorities. The company's focus on innovative, synthetic antimicrobial solutions positions it to capture a larger share of the rapidly evolving wound care sector, aiming to establish new benchmarks in patient outcomes and therapeutic efficacy.
See full Imbed Biosciences company page
